| scholarly article | Q13442814 |
| P2093 | author name string | John Stagg | |
| Bertrand Allard | |||
| David Allard | |||
| P2860 | cites work | A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor | Q28142246 |
| Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage | Q28214799 | ||
| Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment | Q28250207 | ||
| Autocrine Regulation of Macrophage Activation via Exocytosis of ATP and Activation of P2Y11 Receptor | Q28486037 | ||
| Non-canonical inflammasome activation targets caspase-11 | Q28506831 | ||
| Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion | Q28507222 | ||
| Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death | Q28587863 | ||
| The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice | Q28591991 | ||
| ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. | Q45930388 | ||
| Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. | Q46272404 | ||
| Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs | Q46329285 | ||
| The NLRP3 Inflammasome Renders Cell Death Pro-inflammatory | Q47333293 | ||
| Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth | Q47390109 | ||
| IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. | Q47599849 | ||
| CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells. | Q50078530 | ||
| TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. | Q50092867 | ||
| Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade | Q50996495 | ||
| Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. | Q51590802 | ||
| CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer | Q52763511 | ||
| CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury | Q52768241 | ||
| Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. | Q55619003 | ||
| PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer | Q56898302 | ||
| Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors | Q57176182 | ||
| A dual role for autophagy in a murine model of lung cancer | Q57183947 | ||
| Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates | Q57694776 | ||
| The regulation of skin fibrosis in systemic sclerosis by extracellular ATP via P2Y purinergic receptor | Q58613012 | ||
| Foxp3-dependent programme of regulatory T-cell differentiation | Q59084714 | ||
| Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression | Q59387557 | ||
| CD39 regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function | Q60960593 | ||
| Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD | Q61398598 | ||
| Extracellular ATP and P2 purinergic signalling in the tumour microenvironment | Q61764006 | ||
| The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment | Q62590783 | ||
| The role of NK cells and CD39 in the immunological control of tumor metastases | Q62745785 | ||
| Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation | Q64057012 | ||
| Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis | Q64083944 | ||
| Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity | Q64103683 | ||
| ATP redirects cytokine trafficking and promotes novel membrane TNF signaling microvesicles | Q64229287 | ||
| Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells | Q64238055 | ||
| Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells | Q73086297 | ||
| Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages | Q73535863 | ||
| NTPDase1 controls IL-8 production by human neutrophils | Q84353068 | ||
| A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression | Q88866833 | ||
| Purinergic P2X4 receptors and mitochondrial ATP production regulate T cell migration | Q89077148 | ||
| CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade | Q90254608 | ||
| CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells-Letter | Q90987312 | ||
| IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization | Q91185414 | ||
| Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence | Q91531345 | ||
| Specific Decrease in B-Cell-Derived Extracellular Vesicles Enhances Post-Chemotherapeutic CD8+ T Cell Responses | Q91631670 | ||
| Lipopolysaccharide suppresses T cells by generating extracellular ATP that impairs their mitochondrial function via P2Y11 receptors | Q91760278 | ||
| Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM | Q91928259 | ||
| Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies | Q92217622 | ||
| Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression | Q92764218 | ||
| Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 | Q92955884 | ||
| Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1β-driven venous thrombosis | Q93127409 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice | Q29615615 | ||
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors | Q29615665 | ||
| Immunogenic Cell Death in Cancer Therapy | Q29620118 | ||
| Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance | Q30436506 | ||
| Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses | Q31838449 | ||
| Complete deletion of Cd39 is atheroprotective in apolipoprotein E-deficient mice | Q33867669 | ||
| CD39 is a negative regulator of P2X7-mediated inflammatory cell death in mast cells | Q33948890 | ||
| CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice | Q34091467 | ||
| Activation of macrophages by P2X7-induced microvesicles from myeloid cells is mediated by phospholipids and is partially dependent on TLR4. | Q34103835 | ||
| The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. | Q34131656 | ||
| Vascular CD39/ENTPD1 Directly Promotes Tumor Cell Growth by Scavenging Extracellular Adenosine Triphosphate | Q34633667 | ||
| Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs | Q34655688 | ||
| Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy | Q34681370 | ||
| A2A adenosine receptor protects tumors from antitumor T cells. | Q35016529 | ||
| Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer | Q35136797 | ||
| CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma | Q35941350 | ||
| ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y 2 receptors | Q35987913 | ||
| Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice | Q36007505 | ||
| Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis | Q36040470 | ||
| Immunological mechanisms of the antitumor effects of supplemental oxygenation | Q36269330 | ||
| Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice | Q36357191 | ||
| IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response | Q36390492 | ||
| Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets | Q36542190 | ||
| CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia | Q36664487 | ||
| Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine | Q36691126 | ||
| IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells | Q36694205 | ||
| Ion channels in innate and adaptive immunity | Q36769825 | ||
| Deletion of cd39/entpd1 results in hepatic insulin resistance | Q36842553 | ||
| Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals | Q36853115 | ||
| CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer | Q36991010 | ||
| TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses | Q37169110 | ||
| CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice | Q37351218 | ||
| From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease | Q37377260 | ||
| Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer | Q37390515 | ||
| Genetics of the P2X7 receptor and human disease. | Q37423180 | ||
| Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells | Q37590416 | ||
| IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. | Q37659617 | ||
| Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis. | Q37716974 | ||
| Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease | Q38362602 | ||
| CD73 promotes resistance to HER2/ErbB2 antibody therapy | Q38429189 | ||
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial | Q38601785 | ||
| Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. | Q38835006 | ||
| Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death | Q38835009 | ||
| Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation | Q38843556 | ||
| Extracellular purines, purinergic receptors and tumor growth. | Q38870205 | ||
| Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity | Q38939851 | ||
| Regulatory T Cells: Differentiation and Function | Q38945179 | ||
| The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets | Q39161005 | ||
| Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells | Q39170477 | ||
| Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth | Q39234393 | ||
| The P2X7 Receptor in Infection and Inflammation. | Q39445288 | ||
| Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. | Q39523865 | ||
| Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. | Q39531156 | ||
| Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function | Q39600810 | ||
| Adenosine Inhibition of Lymphocyte-Mediated Cytolysis: Possible Role of Cyclic Adenosine Monophosphate | Q39939596 | ||
| Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. | Q40157257 | ||
| Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment | Q40177099 | ||
| A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. | Q40406120 | ||
| Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses | Q40542302 | ||
| Rapid secretion of interleukin-1beta by microvesicle shedding | Q40765816 | ||
| Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity | Q40806737 | ||
| Genetic variants regulating immune cell levels in health and disease. | Q41229283 | ||
| Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. | Q41675016 | ||
| Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment | Q42094877 | ||
| P2Y₆ receptor inhibition perturbs CCL2-evoked signalling in human monocytic and peripheral blood mononuclear cells | Q42101139 | ||
| CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4+T effector cells in patients with head and neck squamous cell carcinoma | Q42212665 | ||
| Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. | Q42794018 | ||
| Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis | Q42955253 | ||
| Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis | Q43044973 | ||
| Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion | Q43111624 | ||
| The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells | Q43628934 | ||
| NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases | Q44483781 | ||
| Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells | Q44612983 | ||
| T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response | Q45292627 | ||
| Anti-CD73 therapy impairs tumor angiogenesis | Q45737780 | ||
| Role of ADP receptors on platelets in the growth of ovarian cancer | Q45869485 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P577 | publication date | 2020-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | On the mechanism of anti-CD39 immune checkpoint therapy | |
| P478 | volume | 8 |
Search more.